EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC-ND 4.0

De-escalation of neoadjuvant taxane and carboplatin therapy in HER2-positive breast cancer with dual HER2 blockade: a multicenter real-world experience in China

Song Wu, Li Bian, Haibo Wang, Shaohua Zhang, Tao Wang, Zhigang Yu, Jianbin Li, Feng Li, Kun Wang, Zefei Jiang

World Journal of Surgical Oncology · 2024

DOI: 10.1186/s12957-024-03468-5 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift World Journal of Surgical Oncology, 2024. Verfasst von Song Wu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Breast Oncology, The Fifth Medical Center of Chinese PLA General Hospital, No.8 East Street, Beijing, 100071, China. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Carboplatin, Neoadjuvant Therapy. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Beijing Science and Technology Project, The innovative project of PLA general hospital.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: TCbHP (taxane + carboplatin + trastuzumab + pertuzumab) is the preferred neoadjuvant therapy regimen for human epidermal growth factor receptor 2 (HER2)-positive breast cancer. However, no consensus exists regarding whether specific populations may be exempt from carboplatin, allowing for de-escalation to the THP (taxane + trastuzumab + pertuzumab) regimen. Additionally, the optimal number of cycles for neoadjuvant THP remains unclear. We compared the efficacy and safety of neoadjuvant TCbHP and THP regimens, providing clinicians with a nuanced perspective to guide their treatment regimen selection. METHODS: This multicenter real-world study included patients with HER2-positive breast cancer undergoing neoadjuvant TCbHP or THP between March 2019 and February 2023. Efficacy was assessed through the pathological complete response (pCR) rate, while safety was evaluated through monitoring adverse events. RESULTS: Among 220 patients, 103 received 6 cycles of TCbHP (TCbHP×6), 83 received 6 cycles of THP (THP×6), and 34 received 4 cycles of THP (THP×4). The TCbHP×6 cohort exhibited a 66% pCR rate compared with 53% in the THP×6 cohort (P = 0.072). Subgroup analysis revealed that in patients aged ≤ 50 years, those with hormone receptor (HR)-negative status, and those with clinical stage T2, the pCR rate of the TCbHP×6 regimen was significantly higher than the THP×6 regimen (P 50, ≤60 years with HR-negative status or clinical stage T2-4. For patients in compromised general condition or lacking the specified indications, the THP×6 regimen emerges as a lower-toxicity alternative with satisfactory efficacy. To ensure treatment efficacy, a minimum of 6 cycles of neoadjuvant THP is required.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsCarboplatinNeoadjuvant TherapyErb-b2 Receptor Tyrosine KinasesTaxoidsAdultAgedFemaleHumansMiddle AgedAntibodies, Monoclonal, HumanizedBridged-Ring CompoundsChinaFollow-Up StudiesPrognosisRetrospective StudiesTrastuzumabDose-Response Relationship, Drug

Stichwörter der Autor:innen

Breast cancerCarboplatinHuman epidermal growth factor receptor 2Neoadjuvant therapyPathological complete response

Substanzen

Antibodies, Monoclonal, HumanizedBridged-Ring CompoundsCarboplatinErb-b2 Receptor Tyrosine KinasesTaxoidsTrastuzumabERBB2 protein, humanpertuzumabtaxane

Autor:innen und Institutionen

  • Department of Breast Oncology, The Fifth Medical Center of Chinese PLA General Hospital, No.8 East Street, Beijing, 100071, China.
  • Breast Disease Center, The Affiliated Hospital of Qingdao University, Qingdao, China.
  • Department of Breast Surgery, The Second Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China.
  • Department of Breast Cancer, Cancer Center, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, No. 106 Zhongshan Second Road, Guangzhou, 510080, China. gzwangkun@126.com.
  • Department of Breast Oncology, The Fifth Medical Center of Chinese PLA General Hospital, No.8 East Street, Beijing, 100071, China. jiangzefei@csco.org.cn.

Förderung

  • Beijing Science and Technology Project
  • The innovative project of PLA general hospital

Zitieren

APA

Wu, S., Bian, L., Wang, H., Zhang, S., Wang, T., Yu, Z., Li, J., Li, F., Wang, K., & Jiang, Z. (2024). De-escalation of neoadjuvant taxane and carboplatin therapy in HER2-positive breast cancer with dual HER2 blockade: a multicenter real-world experience in China. World Journal of Surgical Oncology. https://doi.org/10.1186/s12957-024-03468-5

Vancouver

Wu S, Bian L, Wang H, Zhang S, Wang T, Yu Z, et al. De-escalation of neoadjuvant taxane and carboplatin therapy in HER2-positive breast cancer with dual HER2 blockade: a multicenter real-world experience in China. World Journal of Surgical Oncology. 2024. doi:10.1186/s12957-024-03468-5

BibTeX
@article{Wu2024,
  author = {Wu, Song and Bian, Li and Wang, Haibo and Zhang, Shaohua and Wang, Tao and Yu, Zhigang and Li, Jianbin and Li, Feng and Wang, Kun and Jiang, Zefei},
  title = {De-escalation of neoadjuvant taxane and carboplatin therapy in HER2-positive breast cancer with dual HER2 blockade: a multicenter real-world experience in China},
  journal = {World Journal of Surgical Oncology},
  year = {2024},
  doi = {10.1186/s12957-024-03468-5}
}
Kostenlos starten →